The international research consortium led by Leitat had their final meeting this month in Barcelona and finalized the first prototype of the biosensor.
Barcelona, May 30, 2019 – GLAM is a European research project that developed a sensor able to detect multiple bladder cancer biomarkers from a few drops of urine. The device, based on photonic and monoclonal antibody biosensor technologies, shows various advantages compared to current techniques: it is fast, ultra-sensitive, simple to use, portable, and cheap. The project was coordinated by Leitat and involved 9 other partners from 6 different EU countries: the Institute for Bioengineering of Catalonia (IBEC) and the Institute of Photonic Sciences (ICFO) in Spain, the University of Twente and Radboud University Medical Center in the Netherlands, WizSoft in Israel, the Université Libre de Bruxelles (ULB) and Obelis S.A. in Belgium, Novelic in Serbia, and Optocap in the UK.
During the last 4 years, the partners created a prototype of the sensor, which can detect up to 10 biomarkers in urine. This will help oncologists make better treatment decisions according to the patient’s needs in a non-invasive manner for bladder cancer diagnosis. Moreover, the consortium published several papers and applied for a patent. GLAM had a budget of 4’835’586 euros, financed through the EU’s Horizon 2020 research programme.
According to Francesc Mitjans, technical project coordinator at Leitat, “This is a step towards truly personalized medicine in cancer. The device might allow the identification of new prognostic patterns for a better classification of patients, prognosis evaluation and treatment decision.”
+34 93 788 23 00
+34 699 05 04 81